In 2020, Stryker’s selling, general and administrative expenses included charges related to impairments of a new global ERP system that was in process of being developed for future deployment, reflecting continued investment in enterprise IT infrastructure, while research, development and engineering expenses encompassed projects to develop new products, investments in new technologies and the integration of recent acquisitions; notably, the acquisition of Orthosensor, described as a leader in the digital evolution of musculoskeletal care and sensor technology for total joint replacement, highlights the firm’s emphasis on expanding digital capabilities, and these integration activities and technology investments were partially offset by operating expense savings actions taken in response to pandemic-related constraints, indicating a strategic reallocation of resources to support business needs, operational flexibility and the coordination of internal processes.